
ProQR Therapeutics fell 42.4% from $2.05 to $1.18, behind the S&P 500's +11.2%. Its worst day was Nov 16 (−16.3%), and its low came Nov 16 at $1.18.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
ProQR Therapeutics shares fell 14.1%, while the S&P 500 rose 0.1%.
−14.1% · S&P 500 +0.1%
ProQR Therapeutics closed at its highest level of the year, 19.5% above where the year started.
+5.2% · S&P 500 −0.2%
Story events cover the past 12 months · Times ET
ProQR Therapeutics shares fell 15.7%, while the S&P 500 rose 0.7%.
−15.7% · S&P 500 +0.7%
ProQR Therapeutics shares rose 13.3%, while the S&P 500 rose 0.7%.
+13.3% · S&P 500 +0.7%
EPS of $-0.09 missed the $-0.08 estimate on $5.5M revenue (est. $8.6M).
−5.0% · S&P 500 −1.5%
EPS of $-0.15 beat the $-0.15 estimate on $2.4M revenue (est. $5.5M).
−0.6% · S&P 500 −0.2%
ProQR Therapeutics shares rose 13.2%, while the S&P 500 rose 1.0%.
+13.2% · S&P 500 +1.0%
ProQR Therapeutics shares rose 19.6%, while the S&P 500 rose 1.6%.
+19.6%, the year's best day · S&P 500 +1.6%
EPS of $-0.09 beat the $-0.14 estimate on $10.2M revenue (est. $5.6M).
−0.5% · S&P 500 +0.7%
EPS of $-0.10 beat the $-0.11 estimate on $5.9M revenue (est. $5.3M).
+7.9% · S&P 500 −0.4%
Where it ended: a close of $1.18 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.14, revenue est. $5.0M).
Nothing in the past 12 months.
All PRQR dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PRQR and SPY from Benzinga historical bars. Not investment advice.